Dr. Keaton is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
805 Pamplico Hwy Ste 315
Florence, SC 29505Phone+1 843-674-6460
Education & Training
San Antonio Uniformed Services Health Education ConsortiumFellowship, Hematology and Medical Oncology, 1986 - 1989- San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 1983 - 1986
Medical College of Georgia at Augusta UniversityClass of 1983
Certifications & Licensure
HI State Medical License 2021 - 2026
CO State Medical License 2023 - 2025
GA State Medical License 1986 - 2025
MT State Medical License 2023 - 2025
SC State Medical License 2017 - 2025
SD State Medical License Active through 2025
WI State Medical License 2021 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Awards, Honors, & Recognition
- Fellowship American Board of Internal Medicine
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013
Clinical Trials
- Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Start of enrollment: 2003 Jan 01
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Publications & Presentations
PubMed
- 3 citationsAnti-HER-2 therapy following severe trastuzumab-induced cardiac toxicityIbrahim Sadek, Mark Robert Keaton, Nita J. Maihle, Shou Ching Tang
Genes & Diseases. 2017-09-01 - 17 citationsTITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancerDenise A. Yardley, Edward Arrowsmith, Brooke R. Daniel, Janice F. Eakle, Adam Brufsky
Breast Cancer Research and Treatment. 2017-05-15 - 43 citationsA phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinomaAndrew H. Ko, Hagop Youssoufian, Jayne Gurtler, Karel Dicke, Omar Kayaleh
Investigational New Drugs. 2012-08-01
Journal Articles
- A Phase II study of carbetimer in non-small cell lung cancerKeaton M, Brown T,Craig J et al, Invest New Drugs, 11/8/1990
Press Mentions
A Second Opinion Leads to a New Treatment PlanOctober 1st, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
